Judge Rules TKT Infringes Amgen Erythropoietin Patents
A federal judge has ruled in biotech company Amgen Inc.'s favor in its seven-year legal battle against Transkaryotic Therapies Inc. (TKT) and Aventis Pharmaceuticals Inc. over patents for an anemia treatment....To view the full article, register now.
Already a subscriber? Click here to view full article